Resources

Pharmacokinetics in mice… or a microfluidic device!

Are you still using xenograft models? Looking for more translatable results? Discover how our oncology services can help you today.

A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models

Singh et al., 2022

This publication demonstrates the Microformulators capability to incorporate replicated PK exposures into cellular assays to improve in vitro–in vivo translation understanding. This is demonstrated through comparisons to traditional fixed dose in vitro studies and in vivo xenograft models.

Bridging Gaps in Translational Biology

Petreus et al

Developing effective oncology therapies involves defining the right schedules to minimize side effects and maximise efficacy. This requires an accurate understanding of the pharmacokinetic/pharmacodynamics PK/PD relationship of the compound(s). Animal and human PKs can differ significantly and many failures of novel therapies are due to a missing physiologically relevant link between preclinical and clinical data.​

β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development

Rao et al., 2021

This study shows the effect of the presence of β2-spectrin (SPTBN1) in the promotion of sterol regulatory element (SRE)–binding protein (SREBP)–stimulated lipogenesis. These findings suggest SPTBN1 could be a potential target for a therapeutic against NASH and liver cancer.

Pharmacokinetic profiles revisited in 3D microfluidic tumour models

Petreus et al

The efficacy or toxicity of a drug is dependent on the concentration at the target. Current preclinical models mainly rely on in vivo animal studies which often lack translatability to the human. Here, we demonstrate the potential of a new in vitro MPS approach to better predict human PK and improve in vitro to in vivo translational relevance.

Changing Times, Why Pharmacokinetics Matter in Drug Discovery

Ready to unlock new human-relevant information through our new Oncology Service? This blog discusses all the challenges in drug discovery today and why our Oncology Services could be the missing tool in your toolbox.

Bringing Life to PK Profiles: In Vivo-Relevance From an In Vitro Environment.

Webinar Series 3 Episode 4:

In this webinar, we introduce a new MPS platform designed to address these challenges: the PhysioMimix™ PK – a novel microformulator developed by CN Bio

IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment

Clark et al., 2021

This study elucidated using our MPS platform that CXCR3 ligands were elevated in growing populations of metastatic cancer cells while remaining at physiological levels in the dormant cancer cell site. Upon stimulation with IP-10, dormant cancer cells resulted in a dose-dependent emergence with the metastatic environment playing a significant role.

A Microphysiological Model of Metastatic Progression: Using systems to model metastatic progression

Webinar Series 2 Episode 3:

In this webinar, Dr Amanda Clark, University of Pittsburgh, discusses how to use a Liver MPS to model metastatic progression, evaluate therapeutics and improve our understanding of the bidirectional crosstalk that occurs between host tissue cells and metastatic cancer cells.

Investigating the PK/PD/efficacy relationship of PI3K inhibitors in vitro, enabled by a microfluidic addition and removal device

Singh et al

Characterizing the relationship between pharmacokinetics (PK), pharmacodynamics (PD), and efficacy is critical in the discovery and development of new drugs, schedules, and combinations. This study explores an in vitro methodology using a device capable of recapitulating in vivo PK-like profiles in vitro.

In vitro assessment of combination dosing regimen with in vivo-like pharmacokinetic concentration profiles enabled by a microfluidic addition and removal device

Golby et al

The pharmacokinetic (PK) profile is a determining factor in both the safety and efficacy of a drug or therapeutic regimen. PK profiles can vary significantly between patients and between humans and pre-clinical animal species.​

Here we describe a device capable of recapitulating PK-like profiles in vitro and explore the effects of PK on the treatment of non-small-cell lung carcinoma in mono and combination therapy.